[CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
D000368:Aged; D001545:Benserazide / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D004873:Ergolines; D006834:Hydrazines; D001971:Bromocriptine; D007980:Levodopa; D001545:Benserazide; D002262:Carboxy-Lyases; D002230:Carbidopa
CB 154 nel trattamento del morbo di Parkinson. Risultati in associazione con L-DOPA + IDD